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CHAPTER 1
Introduction
1.1 Depression
The onset of major depressive disorder (MDD), or depression, can happen at all ages and
overall is considered to be the largest contributor to disabilities. Worldwide, over 300 million
people experience some form of depression.(1) Various forms of depression can develop.(2) These
include persistent depressive disorder, which is having a depressed mood for two or more years;
postpartum depression, an onset of depressed mood among women who are pregnant or postdelivery; psychotic depression, suffering from severe depression along with a form of psychosis;
and seasonal affective disorder, onset of depression during the wintertime.(2) MDD is one of the
most prevalent psychiatric disorders; an episode is diagnosed based on having the presence of five
or more of specific symptoms that need to be persistent for at least two weeks while affecting one’s
mood, cognition, and behavior. All of these symptoms happen on a nearly daily basis and include
depressed mood, fatigue, weight or appetite fluctuations, feeling worthless or unreasonably guilty,
inability to think or concentrate, lack of interest or decreased ability to find pleasure in normal
activities, recurrent thoughts of death/suicidal ideation, sleep disturbances, and psychomotor
retardation or agitation.(2; 3; 4) Having just one episode of major depressive disorder is a risk factor
for relapse – up to 85% of those who suffer from an episode may experience a relapse. (3; 5)
Nationwide, numerous Americans also suffer from depression: a survey done showed that 13.3%
of adolescents, 12-17 years old, and 7.1% of adults had at least one instance of an episode of major
depression during 2017; in both groups, a major depressive episode was more prevalent in females
than in males.(4)
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Depression can affect quality of life and may be related to having a higher likelihood of
comorbidities such as stroke, metabolic syndrome, and increased risk of mortality from
cardiovascular disease.(6) Dementia and depression are also believed to be correlated; however, it
is unknown whether depression is a result of dementia, vice versa, or depression and dementia
coexist, yet are unrelated.(6; 7) Depression is also a symptom that is prevalent in neurodegenerative
diseases, such as Alzheimer’s disease and Parkinson’s disease.(7; 8; 9)
Multiple hypotheses exist as to the biochemical cause of depression (Figure 1.1), with the
monoamine hypothesis as the prevailing thought; which includes both the catecholamine and
serotonin hypotheses.(10) The catecholamine hypothesis states that depression is caused by a
catecholamine deficiency, especially norepinephrine, while mania is caused by an excess of
catecholamines at critical brain synapses.(11; 12) Initially, it was believed that serotonin was not
involved in the incidence of depression; however, this thought process changed with the creation
and administration of selective serotonin reuptake inhibitors (SSRIs), observing that the depletion
of tryptophan in formerly depressed patients could lead to a relapse, and observing a relationship
between severely depressed patients and decreased plasma tryptophan.(13; 14)
Current

treatment

of depression involves

utilization of psychotherapies and

pharmaceuticals. There are multiple types of antidepressant medications, including the first
generation of antidepressants, monoamine oxidase inhibitors (MAOIs) and tricyclic
antidepressants (TCAs); and the second generation, norepinephrine and dopamine reuptake
inhibitors (NDRIs), selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine
reuptake inhibitors (SNRIs), serotonin antagonist and reuptake inhibitors (SARIs). (15) While these
classes of antidepressants have side effects specific to their class, such as patients who take SSRIs
are more likely to develop osteoporosis, there are many common side effects with nutritional and
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gastrointestinal implications, including changes in weight, loss of appetite, nausea, vomiting,
diarrhea, and constipation.(15;

16)

Antidepressants also can take 2-4 weeks for noticeable

improvement, which may be discouraging to patients and result in decreased adherence to
treatment plans.(2; 15)

Figure 1.1: Potential Hypotheses of Depression. The top oval shows the possible causes of
depression, along with their associated drug targets; the middle oval is representative of biological
processes that are involved in the etiology of depression; the bottom oval shows the heterogeneity
of the disease, including etiology, diagnosis, and manifestation.(10)
1.2 Serotonin
Serotonin, or 5-hydroxytryptamine (5-HT) was first identified in the 1940s, as a
vasoconstrictor.(16) Since then, it has been found to play a role in cognition, mood, appetite, and
sleep.(17; 18; 19) Low levels of serotonin have been found to be associated with depression. (14) It is
now known that the majority of serotonin is found peripherally: approximately 90-95% of

4
serotonin is found in the enterochromaffin cells, regulating intestinal mobility. The remaining ~510% is found in the brain where it functions as a neurotransmitter.(17)
Neurotransmitters, such as serotonin, allow for neurons in the brain to communicate with each
other via chemical signals, which is necessary for proper functioning of the central nervous system.
For this to happen, the enzymes and compounds required to synthesize the neurotransmitter must
be present in the presynaptic cell. The neurotransmitter is then packaged, and the vesicle attaches
to the bottom of the presynaptic cell. Entry of calcium into the presynaptic cell allows for
depolarization to occur, which releases the neurotransmitter into the postsynaptic terminal. Here,
the correct, specific receptors must be present to allow for the neurotransmitter to be able to bind
to the postsynaptic cell.(20)
Tryptophan (TRP), an essential amino acid, can be metabolized through the kynurenine
pathway, to quinolinic acid and kynurenic acid, which have neurotoxic and neuroprotective
properties, respectively via interaction with the gamma-aminobutyric acid (GABA) receptor.
Further, it can also be metabolized into serotonin (Figure 1.2). The hydroxylation of tryptophan
into serotonin’s precursor, 5-hydroxytryptophan, is carried out via the rate-limiting enzyme,
tryptophan hydroxylase.(21) Serotonin is then synthesized by the enzyme, aromatic amino acid
decarboxylase; serotonin can be further degraded to 5-hydroxyindoleacetic acid and melatonin by
serotonin-N-acetyltransferase and hydroxyindole-O-methyltransferase.(22) Serotonin is unable to
cross the blood-brain barrier (BBB); however, the precursors tryptophan and 5-hydroxytryptophan
can.(23; 24; 25)
The first-generation antidepressants, MAOIs and TCAs, were designed by chance, and worked
through interactions with multiple receptor sites; however numerous side effects resulted. This led
to rational drug development in the late 1960s, as evidence started to suggest that serotonin plays

5
a significant role in the incidence of MDD, leading to a focus on inhibiting the reuptake of
serotonin.(26; 27) Research by Carlsson and colleagues suggested that imipramine, a TCA, may
alleviate depression by not only targeting noradrenaline, but also through blocking the reuptake of
serotonin.(28;

29)

This led to the development of SSRIs, which are currently one of the most

prescribed pharmaceuticals for treating depression. They function by focusing more specifically
on serotonin, and serotonin receptors (SERT); they bind to the serotonin receptor, which allows
for the accumulation of serotonin within the synapse once released due to not being transported
back into the neuron.(30) The first SSRI, zimeldine (Zelmid), was introduced to the market in
Europe through the Swedish pharmaceutical company Astra AB in 1982; however, it was removed
from the market after 16 months due to adverse side effects, including causing Guillain-Barre
syndrome and hypersensitivity.(27) Fluoxetine (Prozac) was being investigated at the same time
due to its potential as an SSRI, with a comparatively weak affinity for the norepinephrine
transporter; it was approved in December of 1987 by the FDA, and introduced to the market in
January of 1988, and is still prescribed today as an antidepressant, as well as to treat bulimia
nervosa, obsessive compulsive disorder, and panic disorder.(27; 31)
However, SSRIs are only able to treat the symptoms of depression, can take weeks for patients
to see any effects of treatment, can result in a relapse of depression, and may lead to adverse side
effects such as abnormally low blood sodium levels, sedation, or gastric irritation.(10; 32) Also,
taking SSRIs in combination with other classes of antidepressants or excess intake of SSRIs due
to uninformed or unaware patients may lead to serotonin syndrome/toxicity, which may even be
fatal.(33; 34) To determine if a patient is suffering from serotonin toxicity, diagnostic criteria has
been developed due to the lack of availability of laboratory tests; some of the criteria involve taking
or increasing the dosage of a serotonergic agent; symptoms including elevated mood, coma, altered
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consciousness, hyper/hypotension, restlessness, and diarrhea; and having symptoms that are not
from a preexisting psychiatric disorder.(33; 34) Discovering a treatment that treats the disease as
opposed to just reducing symptoms, is more effective, and has fewer adverse effects is important
for improving quality of life and decreasing the global burden of illness.

Figure 1.2: Metabolism of tryptophan. NAS – N-acetylserotonin; IFNG – interferon-gamma;
IDO – indoleamine 2,3-dioxygenase; TDO – 2,3-dioxygenase tryptophan(35)
1.3 Nutraceuticals
The saying “let thy food be thy medicine and medicine be thy food”,(36) commonly
attributed to Hippocrates, is a thought process that still prevails in certain traditional medicinal
practices, such as Ayurveda and Traditional Chinese Medicine, where nutrition is believed to play
a role in disease prevention. In the westernized world, the initial thought of nutrition was not
related to disease prevention; instead, due to the population expansion, food that was safe while
providing enough energy and nutrients was the most important concern. (36; 37) More recently,
awareness of the importance of a balance between nutrition and a healthy lifestyle has become
more prominent, eliciting an increase in multidisciplinary research in an attempt to increase the
overall quality of life.(36; 37)
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The term nutraceutical was first used by Dr. Stephen DeFelice in 1989, combining the
words nutrition and pharmaceuticals. He defined it is “a food or part of a food, such as a dietary
supplement, that has a medical or health benefit, including the prevention and treatment of
disease”.(38; 39; 40) Foods and beverages rich in phenolic content, such as fruits, chocolate, tea, and
coffee fit within this category, and exhibit many promising properties, including antioxidant, antiinflammatory, anticarcinogenic, antiviral, anticancer, and neuroprotective.(41)
The Canadian Network for Mood and Anxiety Treatments (CANMAT) has recommended
certain dietary agents that have been examined for their potential to reduce the depressive side
effects seen in those with MDD, including omega-3 fatty acids, saffron, S-Adenosyl-L-Methionine
(SAM), folate, lavender, acetyl-L-carnitine (ALC), dehydroepiandrosterone (DHEA), and St.
John’s Wort; however, more research is being done on other agents such as curcumin, citicoline,
vitamin D, vitamin C, inositol, and tryptophan, with results that are currently inconclusive. (42; 43)
1.4 Curcumin
The bioactive constituent of Curcuma longa, also known as turmeric, is the polyphenol,
curcumin.(44) It is fat-soluble, used as a spice, and as a coloring agent, giving foods a yellow color.
Although medicinally, curcumin has been consumed for thousands of years, it wasn’t officially
discovered until a couple of centuries ago, in the early 1800s, by Vogel and Pelletier.(45; 46) The
rest of the 19th century was spent working on identification of the structure; in 1910 the structure
was finally identified, and then work began towards synthesis of the compound (Figure 1.3).(46; 47)
During the mid-1940s the first paper on biological characteristics of curcumin was published;
Schraufstätter and Brent reported curcumin exhibited anti-bacterial properties; inhibiting the
growth of Staphylococcus aureus, Salmonella paratyphi, Trichophyton gypseum, and
Mycobacterium tuberculosis.(48) Following that publication, other research has shown that
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curcumin exhibits other properties as well, including neuroprotective, anti-inflammatory, antioxidative, and anti-cancer, anti-diabetic, and an ability to lower cholesterol.(44; 49; 50; 51; 52) An
individual’s ability to absorb curcumin is low due to the compound’s poor bioavailability,
although, with the addition of other compounds such as piperine the bioavailability does
increase.(44) Due to curcumin having a low bioavailability, dosage for treatment becomes an
important focus. It is imperative to ensure that an individual gets a large enough dosage of
curcumin for there to be a noticeable and positive effect. However, too high of a dose may be toxic,
but reported side effects of curcumin toxicity are mild, including nausea, diarrhea, and dizziness
in humans, with unknown long-term side effects; although in some cell lines adverse effects,
including inhibition of cytochrome P450 activity and nuclear and mitochondrial DNA damage
were observed.(44; 49; 53)
Curcumin has demonstrated antidepressant effects; a meta-analysis examined the effects
of curcumin on depression in humans, and even though some studies showed no significant effect
of treated patients as compared to the control there was still evidence of reduction in anxiety and
depressive symptoms.(53) A pilot study has shown that an anti-inflammatory drug, acetylsalicyclic
acid (ASA) in addition to antidepressants may improve symptoms of those suffering with
depression in a shorter time, leading to increased compliance with treatment regimen, suggesting
that other anti-inflammatory compounds, such as curcumin, may exhibit a similar effect.(54)
Curcumin’s anti-inflammatory properties indicates that it may also be able to enhance
treatment outcomes when given in addition to an antidepressant drug; a study conducted in rats
induced with a stressor led to increased protein level of indoleamine-2, 3-dioxygenase (IDO), as
well as an increase in the kynurenine (KYN) and KYN/TRP ratio, with a concurrent decrease in
serotonin levels; rats that were induced with a stressor but also receiving an oral gavage of
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curcumin resulted in a significantly decreased protein level of IDO, significantly decreased levels
of KYN and KYN/TRP, and significantly elevated levels of serotonin with respect to the stress
induced group, suggesting that the anti-inflammatory effects of curcumin may be part of the
mechanism of curcumin’s antidepressant properties.(55) Previously in our lab, we investigated the
effect of curcumin on a high cholesterol diet induced Alzheimer’s model. In addition to alleviating
markers of the disease, including amyloid β deposition, using the metabolomics technique we
observed an impact on the tryptophan/serotonin pathway. Thus the purpose of the current study
was to determine if curcumin also exhibits antidepressant properties within a neuronal rat cell line.

Figure 1.3: Structure of curcumin(56)
1.5 Oil Palm Phenolics
Elaeis guineensis jacq, the African oil palm, is the highest oil producing plant, and is
believed to have originated in West Africa, with evidence suggesting the existence of this plant as
early as 3000 BC in Egypt. However, the current leading manufacturers are in the southeastern
Asian region, specifically Indonesia and Malaysia. (57; 58) The kernel of the fruit is where palm
kernel oil is extracted from, commonly used in oleochemical applications. The edible portion, palm
oil, is extracted from the mesocarp of the oil palm; oil palm phenolics (OPP) are the phenolic
compounds that get dissolved and are removed in the aqueous waste product during the process of
oil extraction. As determined by high-pressure liquid chromatography (HPLC) analysis, oil palm
phenolics have a high concentration of the three isomers of caffeoylshikimic acid, p-
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hydroxybenzoic acid, protocatechuic acid, hydroxytyrosol, and gallic acid; also present in
substantial amounts is 2,3-dihydroxybenzoic acid, chlorogenic acid, caffeic acid, and ferulic
acid.(59; 60)
OPP has been reported to have antioxidant and anticancer properties; it may also offer
protection against diabetes.(61; 62; 63) Based on a study done by Sambanthamurthi et al., OPP may
also have cardioprotective effects: OPP was found to dose-dependently inhibit the copper mediated
oxidation of human LDL in vitro; they also observed a relaxation in the aorta and resistant vessels
in rat tissue, suggesting that OPP has the potential to lower blood pressure throughout the whole
organism.(59)
Resveratrol, a phenolic compound that is found in wine, grapes, berries, and peanuts, has
been reported to exhibit beneficial properties, including antioxidative, anticancer, antiinflammatory, cardioprotective, and neuroprotective. Although the mechanism is not fully
understood, a few studies have also suggested that resveratrol may exhibit anti-depressant
properties: Xu et al. found elevated serotonin levels in the frontal cortex, hippocampus, and
hypothalamus of mice along antidepressant effects, while Ahmed et al. saw restoration of serotonin
levels with treatment of resveratrol in rats induced with depression. (64; 65) Since resveratrol and
OPP are both phenolic compounds, and share certain properties such as antioxidative and
anticancer, they may share similar antidepressant properties as well.
Furthermore, previous work in the lab in a high cholesterol diet induced model of
Alzheimer’s disease suggested that OPP is able to modulate the tryptophan pathway, observing
elevated levels of serotonin through plasma and urinary metabolomics.(66; 67) Because of this we
wanted investigate the effects of OPP on the serotonin pathway in a neuronal cell line to see if it
would be able to be a potential agent for the management of depression.
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1.6 RN46A-B14 Cell line
For this study a neuronal rat cell line, biologically from embryonic (day 13) medullary
raphe, was used. This cell line, RN46A-B14, was supplied by the European Collection of Cell
Cultures (ECACC; Salisbury, United Kingdom) as catalog number 12061303, and was purchased
from CellBank Australia (Westmead, NSW, Australia). The cell line has been described per the
originator of the cell line, Dr. Scott R. Whittemore.(68) These cells were isolated after transfecting
the RN46A cell line with brain-derived neurotrophic factor (BDNF); because of this the RN46AB14 cells are able to secrete and synthesize BDNF, while also able to synthesize serotonin.(68) They
have been infected “with a retrovirus encoding the temperature-sensitive mutant simian
vacuolating virus 40 (SV40) large T antigen”.(69) In a proliferative state, these cells have fibroblastlike morphology; however, increasing the temperature from 33°C to 39°C cause the oncogene
which drives proliferation to be inactivated, resulting in differentiation of the cells to a neuronal
morphology, which is why we wanted to use this cell line to investigate the effects of OPP and
curcumin on depression (Figure 1.4).(68)

Figure 1.4: Morphology of RN46A-B14 cell-line. A) Morphology of the proliferating cells, two
days after passaging, and B) the differentiating cells, eight days after induction of differentiation.
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1.7 Metabolomics
It has been commonplace for branches of science to use the reductionist approach, meaning
that the problem being researched, observed, or diagnosed has been reduced to the simplest level
possible. While this does allow for better understanding of a certain mechanism or area within a
pathway, it does not account for the fact that within a living organism, multiple systems are
working together, as an interconnected network.(70) Systems biology has been an increasingly
popular approach used to study an overall living organism, and involves “omics” sciences –
genomics, transcriptomics, proteomics, and metabolomics (Figure 1.5).(71) Systems biology is less
focused on homeostasis; instead, the idea of dynamic stability is important, which allows for small
alterations to occur, but the summative effect of the changes leads to no change overall.(70)

Figure 1.5: Approach of systems biology. The omics approach is seen here, where each system
can be looked at individually; however, the relationship between all the omics cannot be
downplayed. Changes seen in genomics, transcriptomics, and proteomics may be indicative of
behavior changes present within the organism, while alterations in metabolomics are related to
changes in the current status.(71)
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Metabolomics is the newest branch of the omics approach; it involves the identification
and quantification of small molecular metabolites, at a certain time point similar to taking a picture
of the current functional status of the cells, which is indicative of whether there have been any
positive or negative changes due to adaptations to dietary supplementation or as a response to
stress, respectively.(72) The endometabolome and exometabolome can be both be studied, where
the endometabolome includes all intracellular metabolites, such as cell extract for cell culture
studies and plasma, saliva, and cerebral spinal fluid, for organisms; the exometabolome is
composed of external metabolites that have been excreted, such as the growth media for cell culture
and urine, feces, and saliva for organisms. (73)
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1.8 Hypothesis
Previous data from the lab indicated that supplementation with curcumin and OPP might
attenuate some of the effects seen in rats with hypercholesterolemia induced Alzheimer’s disease.
Examination of urinary metabolomics indicated that curcumin played a role in inhibiting the
neurotoxic pathway of tryptophan metabolism to quinolinic acid, while increasing the presence of
mood-elevating serotonin.(67) The mechanism for curcumin increasing the metabolism of
tryptophan to serotonin is of interest and needs to be better understood. Curcumin and OPP exhibit
similar properties, such as antioxidative and anticancer. Due to the antidepressant effect that has
been seen with supplementation of curcumin, we wanted to investigate whether OPP would act in
a similar way.
Aim 1: To determine the appropriate concentrations or dose of curcumin and OPP treatment
in the proliferating and differentiating neuronal cells using a cell viability assay on the
proliferating cells.
Aim 2: To examine changes in the gene expression of serotonin pathway-related genes, Tph1,
Tph2, Aanat, and Asmt and investigate if there are protein level changes of TPH1 and
TPH2 due to treatment of curcumin and OPP.
Aim 3: To conduct metabolomic analysis on the cell extracts, to evaluate differences between
the proliferating and differentiating cells, as well as any differences in each subset
between curcumin and OPP treatments; identify and quantify which metabolites are
responsible for the differences of metabolic profiles.
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CHAPTER 2
METHODS
2.1 Cell culture
Since RN46A-B14 cells exhibit both proliferative and differentiating properties, specific
cell culture media was needed to be made for each subset. The base for both was 1:1 Dulbecco’s
modified Eagle’s medium/Ham’s F-12 nutrient mixture (DMEM/F-12) (Gibco). For proliferation
of the cells, 10% fetal bovine serum (FBS), 2 mM L-Glutamine, and antibiotics: 0.25 mg/ml
geneticin (G-418) and 0.1 mg/ml hygromycin (Thermo Fisher Scientific) were added to the
DMEM/F12. For differentiation, 0.1% bovine serum albumin (BSA) (Sigma Aldrich), 0.1 mg/ml
hygromycin, 1X N-2 and 1X B-27 supplements (Thermo Fisher Scientific) were added to the
DMEM/F12.
Curcumin (Sigma Aldrich) and oil palm phenolics (Malaysian Palm Oil Board (MPOB),
Malaysia) were used as treatments for the cell culture. In brief, cells were plated into two sets of
150 mm Petri dishes (Thermo Scientific) and fed with proliferation media. One set was for the
proliferating cells, where the cells were seeded, and after 48 hours the media was replaced with
untreated or treated media; the other set of plates were seeded, and after 4 days the plates were
moved to the 39°C incubator with the differentiation media. After an additional 6 days, untreated
or treatment media was added. Both the proliferating and differentiating cells were treated with 6
µM of curcumin, 1.5% OPP (stock solution of 1500 parts per million (ppm) gallic acid equivalents
(GAE)), or dual-treatment of 6 µM and 1.5% OPP for 48 hours prior to sample collection.
RN46A-B14 cells were maintained in T-75 flasks (Fisher Scientific). The proliferating
cells were kept in a humidified incubator (Thermo Fisher Scientific) at 33°C with 5% CO 2. For
inducement of differentiation, proliferating cells at 70-80% confluency were moved into a 39°C
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humidified incubator, also at 5% CO2, with the addition of differentiation media. The cells were
considered fully differentiated after 8 days.
These cells are adherent in nature, so in order to passage the cells, a protocol needed to be
used that allowed for the cells to be detached from the bottom of the flasks. Once 70-80%
confluence was reached in the proliferating cells, phosphate buffered saline (PBS) was added to
the flask to rinse the cells, ensuring that the FBS added to the media was removed; if FBS were
still present in the flask, the trypsin would be inactivated. Trypsin/ethylenediaminetetraacetic acid
(EDTA) (Thermo Fisher Scientific) was added to cleave the cells from the bottom of the flask.
Media was added to collect the cells, and pelleted down via centrifugation, resuspended, and split
into new flasks or plates.
For freezing the proliferating cells, the above steps were followed, but during the
resuspension the media was either a lab-made solution of 90% proliferation media plus 10%
dimethyl sulfoxide (DMSO), or commercial cell culture freezing medium (Thermo Fisher
Scientific). The cells were then placed into 1.2 ml cryovials (Thermo Fisher Scientific) and cooled
in stages to avoid shocking the cells. First, the cells were cooled overnight at -20°C, moved to the
VWR -80°C freezer (Thermo Fisher Scientific) for another 24 hours, and finally placed in liquid
nitrogen for long-term storage.
2.2 Cell Viability Assay
To determine the cell viability of proliferating, treated RN46A-B14 cells in relation to the
control cells, a 3-(4,5–dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)–2-(4-sulfophenyl)-2Htetrazolium (MTS) assay was carried out by using the CellTiter 96® AQueous One Solution Cell
Proliferation Assay (Promega). Briefly, proliferating cells were counted and plated at a volume of
200 µl in a 96-well plate at a density of 5,000 cells per well. After 24 hours, the original media
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was removed, and varying concentrations of curcumin in media (0-20 µM) or OPP in media (010%) was added, with a final volume of 200 µl per well. Then, after 72 hours of treatment, 10 µl
of CellTiter was added to each well. The plate was incubated at 33°C for 1 hour, and the absorbance
was then read on a microplate reader (Biotek ELx800) at 490 nm. The average absorbance of pure
proliferation media was subtracted from the average absorbances of the control and treated cells.
Then the relative cell viability was calculated by dividing the average cell viability (absorbance)
of the treatment by the average cell viability (absorbance) of the control, and multiplying by 100.
Six replicates were used for each condition.
2.3 Real-time quantitative Polymerase Chain Reaction analysis
To determine the expression of genes present in the serotonin pathway, real-time
quantitative polymerase chain reaction (qPCR) analysis was done. The RN46A-B14 cells from
each treatment type were then from the flasks and counted; 2 million cells from all four treatment
conditions of the proliferating and differentiating cells were used for total RNA extraction.
The protocols from QIAshredder and RNeasy Mini Kit (Qiagen) were followed, with an
additional RNA cleanup step done to eliminate the presence of genomic DNA (gDNA)
contamination. Briefly, the cells were lysed and homogenized using the QIAshredder, ethanol was
added to allow the total RNA to bind to the membrane of the column, 3 washes were then done to
eliminate possible contaminants, and the total RNA was eluted; as an additional RNA purification
step, the procedure was repeated, excluding the lysing and homogenization.
Total RNA was then converted to complementary DNA (cDNA) using the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems). Briefly, the total RNA was quantified
using the NanoDrop (Thermo Fisher Scientific); for each sample, 1 µg of total RNA was added to
the reverse transcription master mix, containing random primers, deoxyribose nucleoside
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triphosphate (dNTP) mix, and an RNase inhibitor, with (+RT) or without (-RT) reverse
transcriptase. A thermocycler, Mastercycler® RealPlex4, was used (Eppendorf) to reverse
transcribe the RNA to cDNA by incubating the samples at 25°C for 10 minutes, extending at 37°C
for 120 minutes, heat-inactivating the reverse transcription enzyme at 85°C for 5 minutes, and a
final hold step at 4°C.
To check for contamination, PCR was run, using DreamTaq Green Master Mix (Thermo
Fisher Scientific); the templates were either the +RT and -RT cDNA samples, gDNA as a control,
and a non-template control (NTC) as a negative control; the primer pair succinate dehydrogenase
complex flavoprotein subunit A (Sdha) was used (Table 2.1). The following thermocycler
conditions were used for this step: initial denaturation at 95°C for 3 minutes; 30 cycles of the
following 3 steps: denaturation at 95°C for 30 seconds, annealing at 55°C for 30 seconds, and
extension at 72°C for 60 seconds; a final extension step at 72°C for 15 minutes, the samples were
then held at 4°C, and stored at -20°C.
2% agarose (Fisher Scientific) gels were made and placed in a 1X Tris-borate-EDTA
(TBE) solution (EMD Millipore); the samples from the cDNA synthesis were loaded. After
running the gel, it was then stained with ethidium bromide (Bio Rad, Hercules, CA) to allow for
the bands to be detected. The products from the gDNA were expected to be at 728 bp, while the
cDNA was at 127 bp. If the gDNA band was not present in the +RT samples, and the -RT samples
and NTC did not have any bands, the cDNA was deemed usable for real-time qPCR.
Real-time qPCR was done to quantify the mRNA levels. Primers for Ubiquitin-conjugating
enzyme (Ubc-9), used as a loading control were found in a previously published paper.(74) PrimerBLAST from National Center for Biotechnology Information (NCBI) was used to design the
remaining primers: tryptophan hydroxylase 1 (Tph1), tryptophan hydroxylase 2 (Tph2),
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acetylserotonin O-methyltransferase (Asmt), and aralkylamine N-acetyltransferase (Aanat) (Table
2.1). PowerUp SYBR Green (Applied Biosystems) was used for the master mix. The gene
expression changes are represented as the mean (±SEM) of the fold changes observed in the
proliferating and differentiating cells. For both subsets of cells, fold changes were calculated by
relative comparison of each of the treatments (6 µM curcumin, 1.5% OPP, and dual-treatment) to
the control groups. A minimum of three replicates of RNA from each subset of cells and treatments
were used for this experiment.
Table 2.1: Primers used for gene expression analysis
Gene

Primer orientation Primer sequence (oriented 5’ to 3’)
Forward

GCA GAA GAA GCC ATT TGC GG

Reverse

AGC ACA GTC AGC CTC ATT CAA

Forward

TCG TAC CTT TCT CAC CAC AGT ATC TAG

Reverse

GAA AAC TAA GAC ACC TCC CCA TCA

Forward

ATA CTG TGG CTA TCG GGA AGA C

Reverse

ATG GAA AAC CCT GTG CGT TC

Forward

CCG ACC ACC CAG GAT TCA A

Reverse

TCC CGA AAC ACA ACA CCC CA

Forward

TTC TTC CGT TCC CGC CT

Reverse

ACC ATC AGC CCA GTC GT

Forward

CAC ATC CTT CTC TGC CCA AC

Reverse

TGA CCC TTA CCT CTC TAC TCC AC

Sdha

Ubc-9

Tph1

Tph2

Asmt

Aanat

2.4 Western blotting analysis
To determine the level of TPH1 and TPH2 proteins present within the cells, whole RN46AB14 cell protein extracts were subjected to western blotting analysis. The cells came from the same
150 mm Petri dishes that the cells were obtained for the RNA extraction mentioned in section 2.1;
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however, 4 million cells were used in this step. The cells were pelleted and resuspended in PBS
two times, to wash the cells from any residual media. 1X RIPA buffer and protease inhibitor were
added to the pellet cells, resuspended, and shook on a shaker at 4°C for 15 minutes. The solution
was then centrifuged at 14,000 g for 15 minutes. After this, the supernatant, containing the protein
extract, was carefully removed as to not disturb the pellet containing cell debris, and placed into a
new 1.5 ml tube (Eppendorf), then placed in the -20°C freezer for storage; the remaining cell debris
was discarded.
On the first day of the western blot, the total protein concentration of the samples was
determined by conducting a bicinchoninic acid (BCA) assay (Thermo Scientific). Briefly, eight
known concentrations of bovine serum albumin (BSA) were prepared. 10 µl of each standard and
unknown protein sample were pipetted into a 96-well plate. 200µl of working reagent was then
added to each well. The plate was incubated at 37°C for 30 minutes, and then read with the plate
reader at 570 nm. Normalized protein samples were then prepared, using 25 µg of protein per
sample, with 2-Mercaptoethanol (βME) (Sigma Aldrich) and 1X lane marker reducing sample
buffer (Thermo Fisher Scientific). Samples were loaded into a precast 4–15% Mini-PROTEAN®
TGX Stain-Free™ (Bio Rad) polyacrylamide protein gel; after separation the blots were
transferred onto Trans-Blot® Turbo™ Mini polyvinylidene fluoride (PVDF) membranes (Bio
Rad). The membranes were blocked overnight at 4°C, washed, incubated overnight with the
primary antibody for the target proteins at 4°C, washed, and incubated on a shaker with the
secondary antibody at room temperature for one hour. The protein bands were then detected with
Clarity™ enhanced chemiluminescent (ECL) substrate and read using ChemiDoc™ XRS and
Image Lab software (Bio Rad). The membranes were re-blocked for one hour, washed, re-probed
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with the primary antibody, targeting the loading control protein, overnight at 4°C, washed, and
incubated on a shaker with the secondary antibody at room temperature for one hour, then detected.
The primary antibodies used were TPH1 (1:1000) (Invitrogen), TPH2 (1:500) (Invitrogen),
and β-actin (Cell Signaling); the secondary antibody used was goat-anti-rabbit (H + L) horseradish
peroxidase (HRP) conjugate (1:3000) (Bio Rad), with StrepTactin HRP Conjugate (1:5000) (Bio
Rad). Three replicates were used for this experiment.
2.5 Metabolomics
To collect the exo-metabolome and the endo-metabolome from the RN46A-B14 cells, the
same procedure was followed as is discussed in section 2.1. On the day of sample collection, 2 ml
of media was collected and centrifuged at 4°C, 2,000 g for 5 minutes; 1 ml of the supernatant was
then transferred to a new tube, snap-froze in liquid nitrogen, and stored at -80°C for future analysis.
The following steps were all conducted on ice: the remaining media from the plate was removed,
and the plate was rinsed two times with PBS. Ice cold methanol/water (80:20), pre-chilled at -80°C
overnight, was then added to the plate, and immediately after the plate was scraped vigorously to
collect the cell extract, which was placed in a 2 ml tube. An additional volume of ice-cold
methanol/water (80:20) was added to collect any residual cell extract and then also added to the
same 2 ml tube. The tube then was vortexed and incubated in an ice/ethanol water bath for 5
minutes. The tubes were centrifuged at 4°C, 5,725 g for 5 minutes; the supernatant, containing the
cell extract, was removed and transferred to a new 1.5 ml tube; the 2 ml tube contained the protein
pellet. All tubes were then snap-froze in liquid nitrogen and stored at -80°C; the following day the
cell extract was freeze-dried using the CentriVap benchtop vacuum concentrator (Labconco),
snap-froze, and stored at -80°C until further analysis.
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The day prior to conducting nuclear magnetic resonance (NMR) metabolomic analysis, a
0.5 mM solution of 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) in deuterium oxide (D20)
was prepared. A reference was prepared with the DSS/D20 solution; samples were prepared by
adding the DSS/D20 solution to reconstitute the dried cell extract powder; the samples were
centrifuged and transferred to 5 mm Aldrich® ColorSpec® NMR tubes (Sigma Aldrich) using
Pasteur pipettes (Fisher Scientific).
The Agilent DD2 600 MHz NMR spectrometer was used to acquire spectra for each of the
samples for 1H at a temperature of 25°C at a frequency of 599.73 MHz, 64 scans, and nuclear
Overhauser effect spectroscopy (TNNOESY) was used for the pulse sequence. The spectra were
then imported into the Spectrus Processor (ACD/Labs 9.0), where the free induction decay (FID)
files were Fourier transformed. Batch-processing of the spectra allowed for auto-phasing and
correction of the baseline, using the DSS peak as a reference to set the spectra to 0 ppm; manual
phasing and baseline corrections were done to individual spectrum if needed. Intelligent bucketing
was used to divide the spectra into integrals; the resulting table of common integrals was exported,
as values. This table was imported into soft independent modeling of class analogy (SIMCA 15.0)
(Umetrics) to allow for multivariate analysis.
To identify and quantify metabolites of interest, the FID files were imported into the
Chenomx suite (Chenomx 8.4), Fourier transformed, and then they were individually phased,
baseline corrected, and had the chemical shape and shift indicator (CSI) calibrated to the DSS peak
in the processor application. The profiler application was used to fit the peaks and clusters of each
individual spectra, using DSS as the reference for concentration purposes, and utilizing Chenomx’s
600 MHz library, which is a database of metabolites they have profiled in their system. At least
four replicates were used for each condition of both the proliferating and differentiating cells.
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2.6 Statistical Analysis
Statistical analyses were performed using the unpaired t-test with GraphPad Prism software
8.00 (La Jolla, CA); p values of less than 0.05 were considered statistically significant.
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CHAPTER 3
Results
Aim 1: To determine the appropriate concentrations or dose of curcumin and OPP treatment in the
proliferating and differentiating neuronal cells using a cell viability assay on the
proliferating cells.
3.1 Determination of the acceptable concentrations for curcumin and oil palm phenolics
The RN46A-B14 cell line had not been used in this lab prior to this work. So it was
important to first learn about how the cells grow, and what treatment ranges were acceptable. In
cancer cells, determining the viability of cells is done to see at what point growth inhibition occurs;
this is the desired effect as the focus of cancer treatments is to stop the proliferation of cells.
However, for this study, the purpose was to find a working concentration of curcumin and OPP in
the proliferating cells that would not be overly toxic.
Initially, an MTS assay for curcumin was conducted, using a range of concentrations from
0-20 µM (Figure 3.1). The findings indicated that the addition of 1 µM of curcumin significantly
increased the cell viability in relation to the control while at 15 and 20 µM the growth of the cells
was significantly decreased. At 2-7.5 µM, there was no significant change in cell viability
observed. Even though at 10 µM the curcumin did not have a significant impact on the viability of
the cells, the viability of the cells was less than fifty percent of what the control had. From this, it
was determined that a working range between 1-7.5 µM of curcumin would be appropriate.
An MTS assay was also done for OPP, using concentrations of 0-10% (from a stock
solution of 1500 ppm GAE) (Figure 3.2). Although the viability of the cells was significantly
decreased at all but one concentration of OPP (0.5%), only the 5, 7.5 and 10% samples had cell
viabilities that were around or less than fifty percent of the viability of the control. Due to this, a
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working range of 0.5-3.75% was deemed a suitable range of concentrations for further
experiments.
Aim 2: To examine changes in the gene expression of serotonin pathway-related genes, Tph1,
Tph2, Aanat, and Asmt and investigate if there are protein level changes of TPH1 and TPH2
due to treatment of curcumin and OPP.
3.2 Identify serotonin pathway-related genes regulated by curcumin and OPP
To see if supplementing the proliferation and differentiation media with curcumin and OPP
would impact the serotonin pathway, the expression of serotonin pathway-related genes was
determined. Tryptophan is metabolized to 5-hydroxy-L-tryptophan by tryptophan hydroxylase
(TPH1 or TPH2), dopa decarboxylase (DDC) decarboxylates the 5-hydroxy-L-tryptophan to
serotonin. The acetylation of serotonin to N-acetyl serotonin occurs via arylkylamine Nacetyltransferase (AANAT). Lastly, N-acetyl serotonin is methylated by N-acetylserotonin Omethyltransferase (ASMT), resulting in the synthesis of melatonin. The data from real-time qPCR
showed that there was no significant change in gene expression of Tph1, Tph2, or Asmt in either
the proliferating or differentiating cells (Figure 3.3). A significant increase in Aanat was seen in
proliferating cells treated with curcumin, yet in the differentiating cells, there was a significant
decrease in Aanat with the addition of OPP as well as dual treatment of curcumin and OPP. This
suggests curcumin is able to regulate the expression of Aanat within the proliferating cells, while
OPP is able to regulate the expression of Aanat within the differentiating cells. Furthermore,
curcumin and OPP affect Aanat in an opposite way. These data indicate that curcumin and OPP
may impact the serotonin pathway through influencing Aanat.
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3.3 Level of proteins involved in the metabolism of tryptophan to serotonin
For this experiment, the TPH1 and TPH2 proteins were looked at more closely, as TPH is
the rate-limiting step for the synthesis of serotonin. Consistent with what was seen from the gene
expression data involving Tph1 and Tph2, no alterations in the protein levels of TPH1 or TPH2
was observed in either the proliferating or differentiating cells (Figure 3.4). Taken together, these
data suggest that there is no effect of OPP and curcumin on TPH.
Aim 3: To conduct metabolomic analysis on the cell extracts, to evaluate differences between the
proliferating and differentiating cells, as well as any differences in each subset between
curcumin and OPP treatments; identify and quantify which metabolites are responsible for
the differences in metabolic pathways.
3.4 Identification of metabolomic profiles of proliferating and differentiating cells, under
different treatment conditions
Using the spectra obtained from 1H NMR analysis to conduct the metabolomics approach,
it is possible to ascertain any differences metabolically. As expected, utilizing the RN46A-B14
proliferating cells and inducing differentiation resulted in cells exhibiting different metabolic
profiles (Figure 3.5). In this instance, clear separation between the subtypes of cells is seen, even
with using an unsupervised approach, principal component analysis (PCA), indicating the RN46AB14 proliferating cells and inducing differentiation resulted in cells which exhibit different
metabolic profiles (Figure 3.5). From the PCA plot, it is evident that the proliferating and
differentiating cells have different metabolic profiles, but the effect of treatment of curcumin and
OPP is not able to be seen.
The main focus of this experiment was to observe if treatments had an effect on the
metabolic profiles of the cells. In order to see the effect of treatment, the subtypes of cells had to
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be separated, so that only the proliferating or the differentiating cells were being examined. Along
with examining the subtypes of cells individually, a supervised approach, partial least squares
discriminant analysis (PLS-DA) was also done. For this, each treatment was identified as a class,
causing the differences between treatments to be shown, if applicable. In the proliferating cells,
this led to there being a clear separation between the control and curcumin-treated cells, and the
cells treated with OPP and dual-treatment (Figure 3.5A). Even though the separation was less
evident in the differentiating cells, a similar pattern was observed (Figure 3.5B). These data
suggest that OPP, as a single or dual treatment, may be responsible for the majority of the alteration
of metabolic profiles, with respect to the control. Given that the dual treatment cluster is closer to
the OPP group as compared to the curcumin set, it is possible that OPP, not curcumin, may be
responsible for the majority of the alteration of metabolic profiles in the dual treatment samples.
Next, orthogonal partial least squares discriminant analysis (OPLS-DA) was used to get a
better comparison between the control and each treatment. Figures 3.7-3.9A show the OPLS-DA
scores plots for the proliferating cells and 3.10-3.12A for the differentiating cells: control vs.
curcumin, control vs. OPP, and control vs. dual treatment respectively. Based on the scores plot,
it was observed that every treatment, from both the proliferating and differentiating cells, exhibit
clear separation from the control. This suggests that the treatments do have some effect on cellular
metabolism. To identify the spectral regions that significantly varied between the control and
treatment groups in both the proliferating and differentiating cells, the corresponding S-plot was
generated from the OPLS-DA model (Figures 3.7-3.12B).
These regions were then analyzed further in Chenomx to identify the metabolites that
contributed to the separations, resulting in Table 3.1. Overall, the metabolites that were changed
in either the control or treatment conditions in both proliferating and differentiating cells included
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ATP, alanine, betaine, dimethylamine, glucose, glutamate, glycine, isoleucine, lactate, ophosphocholine, proline, sarcosine, taurine, threonine, sn-glycero-3-phsophocholine, and βalanine. Venn diagrams for the proliferating and differentiating cells were generated to further
examine the relationship between treatment conditions and the metabolites responsible for the
alterations (Figure 3.13). Statistically significant metabolites (p<0.05) in both subsets included
dimethylamine, sarcosine, lactate and glycine, while in the proliferating cells sn-glycero-3phosphocholine, ATP, and betaine were significantly impacted, and in the differentiating cells βalanine and glutamine were significantly impacted. In both subsets of cells, only the curcumin
(both single and dual treatment) treated cells had an alteration in metabolic profile due to sarcosine
and dimethylamine. Lactate was significantly impacted in all treated proliferating cells, while only
the OPP treated differentiating cells were significantly impacted. Significant changes in glycine
were seen in the proliferating cells treated with OPP (single and dual treatment), while in the
differentiating cells a significant impact was only seen in curcumin treated cells. OPP also induced
a significant change in sn-glycero-3-phosphocholine and ATP in the proliferating cells, and βalanine in the differentiating cells; dual treatment of curcumin and OPP significantly impacted
betaine and glutamine in the proliferating and differentiating cells, respectively. This data suggests
that, while the same metabolites are responsible for the alterations in metabolic profiles in both the
proliferating and differentiating cells, the metabolites are not necessarily involved in similar ways.
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Figure 3.1: Determination of cell viability with varying treatment doses of curcumin. An MTS
assay to determine a working range for curcumin was conducted with proliferating RN46A-B14
cells. They were seeded at a density of 5,000 cells per well and treated with varying concentrations
of curcumin, from 0-20 µM, for 72 hours prior to the addition of the MTS solution. After
incubation for one hour, the absorbances were read via a plate reader. Results are the average of
six technical replicates. The vertical axis shows the relative absorbance/viability of the cells as a
percentage, in relation to the control ± standard error of the mean (SEM), shown through the error
bars. The statistical analysis results compare treated RN46A-B14 cells to the control. Significant
differences are shown with * for p <0.05, and *** for p <0.001.
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Figure 3.2: Determination of cell viability with varying treatment concentrations of OPP. An
MTS assay to determine a working range for curcumin was conducted with proliferating RN46AB14 cells. They were seeded at a density of 5,000 cells per well and treated with varying
concentrations of OPP, from 0-10% OPP (from a stock solution of 1500 ppm GAE), for 72 hours
prior to the addition of the MTS solution. After incubation for one hour, the absorbances were read
via a plate reader. Results are the average of six technical replicates. The vertical axis shows the
relative absorbance/viability of the cells as a percentage, in relation to the control ± SEM, shown
through the error bars. The statistical analysis results compare treated RN46A-B14 cells to the
control. Significant differences are shown with * for p <0.05, ** for p<0.01 and *** for p <0.001.
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Figure 3.3: Effect of curcumin, OPP, and dual treatment on the expression of serotoninpathway metabolic genes. Real-time qPCR analysis of total RNA extract from RN46AB14 cellline, (A) proliferating and (B) differentiating cells, treated with 6 µM curcumin, 1.5% OPP (1500
ppm GAE), and dual-treatment of 6 µM curcumin and 1.5% OPP for 48 hours prior to sample
collection. All proliferating samples are compared to the proliferating control cells, whereas all
differentiating samples are compared to the differentiating control cells. Ubc9 was used to
normalize gene expression levels. The results are the average of three biological replicates. The
vertical axis is indicative of the relative mRNA level ± SEM. Statistically significant differences
are indicated with * for p <0.05, *** for p <0.001.
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Figure 3.4: Effect of curcumin and OPP on the protein levels of TPH1 and TPH2 in
proliferating and differentiating RN46A-B14 cells. Total cellular protein was extracted from
RN46A-B14 proliferating and differentiating cells, treated with 6µM of curcumin, 1.5% OPP
(1500 ppm GAE), and dual-treatment of 6 µM curcumin and 1.5% OPP for 48 hours prior to
sample collection, and then subjected to western blot analysis. TPH1 and TPH2 were the target
proteins, and β-actin was used as a loading control. The arrow denotes the protein band of interest
for TPH2.
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Figure 3.5: PCA scores plot of proliferating and differentiating cells, under all treatment
conditions. One spot is representative of one sample: all samples labeled (P) are from proliferating
cells, while (D) are from differentiating cells. The numbers are representative of the treatment
(where 1 is control, 2 is curcumin, 3 is OPP, and 4 is dual treatment of curcumin and OPP) and
replicate number (up to 5 replicates possible per treatment condition), respectively; for example,
P2.4 is from proliferating cells, treated with curcumin, and is the fourth replicate. At least four
biological replicates were used for each treatment condition. All samples were treated with 6 µM
of curcumin, 1.5% OPP, or dual-treatment of curcumin and OPP for 48 hours prior to sample
collection. There is a clear separation seen between all of the proliferating (P) samples and the
differentiating (D) samples.
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Figure 3.6: PLS-DA scores plot of the subtypes of RN46A-B14 cells. One spot is representative
of one sample: all samples in A) are from proliferating cells, while B) are from differentiating
cells. Treatments are indicated by color and number: green/1 are the control samples, yellow/2 are
the curcumin-treated, brown/3 is the OPP-treated, and red/4 is the dual treatment of curcumin and
OPP. The numbers are representative of the treatment and replicate number (up to 5 replicates
possible per treatment condition), respectively. At least four biological replicates were used for
each treatment condition. A) There is a clear separation seen over the t[1] (vertical) axis, separating
the control and curcumin-treated proliferating cells from the cells that were treated with OPP and
dual treatment of curcumin and OPP. B) There is also a separation seen, this time not quite as well
defined, over the t[2] (horizontal) axis, separating most of the control and all of the curcumintreated differentiating cells from the cells that were treated with OPP and dual treatment, of
curcumin and OPP.
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Figure 3.7: OPLS-DA scores plot of the proliferating RN46A-B14 cells, control vs. curcumin.
A) There is a clear separation seen over the t[1] (vertical) axis, separating the control and
curcumin-treated proliferating cells. B) The corresponding S-plot shows which areas within the
NMR spectra may be responsible for the differences in the metabolic profiles; these points
represent metabolites. The points deviating from mid-line in the upper right quadrant are
responsible for alterations in the curcumin-treated cells, while the lower left quadrant shows
changes that may be seen within the control cells. The key metabolites that changed are marked
on the S-plot: glycine, o-phosphocholine, glucose, taurine, isoleucine, sarcosine, dimethylamine,
lactate, threonine, β-Alanine, glutamine, and alanine.
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Figure 3.8: OPLS-DA scores plot of the proliferating RN46A-B14 cells, control vs. OPP.
A) There is a clear separation seen over the t[1] (vertical) axis, separating the control and OPP
treated proliferating cells. B) The corresponding S-plot shows which areas within the NMR spectra
may be responsible for the differences in the metabolic profiles; these points represent metabolites.
The points deviating from mid-line in the upper right quadrant are responsible for alterations in
the OPP treated cells, while the lower left quadrant shows changes that may be seen within the
control cells. The key metabolites that changed are marked on the S-plot: glycine, glutamine,
glutamate, glucose, taurine, sn-glycero-3-phosphocholine, o-phosphocholine, lactate, and
threonine.
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Figure 3.9: OPLS-DA scores plot of the proliferating RN46A-B14 cells, control vs. dual
treatment. A) There is a clear separation seen over the t[1] (vertical) axis, separating the control
and dual treatment of curcumin and OPP treated proliferating cells. B) The corresponding S-plot
shows which areas within the NMR spectra may be responsible for the differences in the metabolic
profiles; these points represent metabolites. The points deviating from mid-line in the upper right
quadrant are responsible for alterations in the cells receiving the dual treatment, while the lower
left quadrant shows changes that may be seen within the control cells. The key metabolites that
changed are marked on the S-plot: glycine, glutamate, glucose, taurine, ATP, proline, sarcosine,
dimethylamine, o-phosphocholine, alanine, lactate, and threonine.
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OPLS-DA scores plot of the differentiating RN46A-B14 cells, control vs. curcumin. A) There
is a clear separation seen over the t[1] (vertical) axis, separating the control and curcumin-treated
differentiating cells. B) The corresponding S-plot shows which areas within the NMR spectra may
be responsible for the differences in the metabolic profiles; these points represent metabolites. The
points deviating from mid-line in the upper right quadrant are responsible for alterations in the
curcumin-treated cells, while the lower left quadrant shows changes that may be seen within the
control cells. The key metabolites that changed are marked on the S-plot: threonine, glucose,
taurine, β-Alanine, glutamine, glutamate, alanine, sarcosine, dimethylamine, lactate, and
threonine.
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Figure 3.11: OPLS-DA scores plot of the differentiating RN46A-B14 cells, control vs. OPP.
A) There is a clear separation seen over the t[1] (vertical) axis, separating the control and OPP
treated differentiating cells. B) The corresponding S-plot shows which areas within the NMR
spectra may be responsible for the differences in the metabolic profiles; these points represent
metabolites. The points deviating from mid-line in the upper right quadrant are responsible for
alterations in the OPP treated cells, while the lower left quadrant shows changes that may be seen
within the control cells. The key metabolites that changed are marked on the S-plot: sn-glycero-3phosphocholine, taurine, glucose, betaine, glutamate, lactate, threonine, and alanine.
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Figure 3.12: OPLS-DA scores plot of the differentiating RN46A-B14 cells, control vs. dual
treatment. A) There is a clear separation seen over the t[1] (vertical) axis, separating the control
and dual treatment of curcumin and OPP treated differentiating cells. B) The corresponding S-plot
shows which areas within the NMR spectra may be responsible for the differences in the metabolic
profiles; these points represent metabolites. The points deviating from mid-line in the upper right
quadrant are responsible for alterations in the cells receiving the dual treatment, while the lower
left quadrant shows changes that may be seen within the control cells. The key metabolites that
changed are marked on the S-plot: glucose, taurine, sn-glycero-3-phosphocholine, β-Alanine,
sarcosine, dimethylamine, glutamate, glutamine, alanine, proline, lactate, and threonine.
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Table 3.1: Metabolite concentrations of RN46A-B14 proliferating and differentiating cells.
List of concentrations of metabolites determined from 1H NMR spectra of RN46A-B14 A)
proliferating cells and B) differentiating cells, treated with 6 µM, 1.5% OPP, or dual-treatment of
curcumin and OPP for 48 hours prior to collection of cell extract. р-values of less than 0.05 were
considered statistically significant.
A)
Control vs. Curcumin
p-value
Metabolite Name
ATP
Alanine
Betaine
Dimethylamine
Glucose
Glutamate
Glutamine
Glycine
Isoleucine
Lactate
o-phosphocholine
Proline
Sarcosine
Taurine
Threonine
sn-glycero-3-phosphocholine
β-Alanine

0.4045
0.3163
0.6210
0.0033
0.9703
0.9281
0.4818
0.0823
0.7804
0.0097
0.6113
0.0505
0.0049
0.1966
0.2245
0.4188
0.7413

Fold
change
0.90
0.88
1.17
16.55
1.01
0.98
0.88
0.83
0.96
1.61
0.92
0.78
11.82
0.70
1.33
0.80
0.96

Control vs. OPP
p-value
0.0019
0.0843
0.1531
1.0000
0.7582
0.4555
0.1885
0.0289
0.0564
0.0053
0.3190
0.1019
1.0000
0.3883
0.5544
0.0408
0.3080

Fold
change
1.48
0.78
1.62
1.00
0.96
0.87
0.74
0.59
0.81
1.74
1.22
0.59
1.00
1.19
1.18
1.63
1.18

Control vs. Dual
Treatment
p-value
Fold
change
0.3737
1.18
0.4185
1.29
0.0317
4.53
0.0040
22.60
0.7072
0.93
0.2864
0.73
0.1179
0.63
0.0002
0.30
0.4161
1.24
0.0012
1.92
0.6709
1.07
0.2838
1.65
0.0169
12.02
0.8068
0.94
0.0944
2.13
0.0804
1.83
0.3737
1.30

B)
Control vs. Curcumin
p-value
Metabolite Name
ATP
Alanine
Betaine
Dimethylamine
Glucose
Glutamate
Glutamine
Glycine
Isoleucine
Lactate
o-phosphocholine
Proline
Sarcosine
Taurine
Threonine
sn-glycero-3-phosphocholine
β-Alanine

0.3843
0.1246
0.7878
0.0220
0.7133
0.0521
0.4744
0.0188
0.6569
0.1345
0.4934
0.1009
0.0189
0.6665
0.3022
0.7216
0.0698

Fold
Change
0.86
0.69
0.90
13.18
1.07
1.42
0.92
0.64
0.94
1.40
1.20
1.51
20.74
0.95
0.79
0.92
1.47

Control vs. OPP
p-value
0.0540
0.4583
0.5500
1.0000
0.6805
0.0518
0.1873
0.0926
0.5850
0.0082
0.1101
0.2818
1.0000
0.5089
0.5158
0.5869
0.0119

Fold
change
1.23
1.10
0.77
1.00
1.07
1.53
0.81
0.79
1.09
1.65
1.42
1.28
1.00
1.13
1.16
1.12
1.71

Control vs. Dual
Treatment
p-value
Fold
change
0.9590
0.99
0.5975
0.89
0.9654
0.98
0.0421
7.13
0.5760
0.90
0.0978
1.50
0.0295
0.69
0.0520
0.67
0.9799
1.00
0.2449
1.30
0.7141
0.91
0.7400
1.14
0.0213
13.35
0.7371
1.07
0.5653
1.21
0.9373
0.98
0.1288
1.65
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Figure 3.13: Venn diagrams of significantly impacted metabolites. Metabolites that were
significantly impacted in A) the proliferating and B) differentiating cells are shown. For the
proliferating cells lactate is seen in control vs. all three treatment conditions; dimethylamine and
sarcosine are seen in both the control vs. curcumin and control vs. dual treatment; glycine is seen
in both control vs. OPP and control vs. dual treatment; ATP and sn-glycero-3-phosphocholine are
significantly impacted in control vs. OPP; and betaine is significantly impacted in control vs. dual
treatment. For the differentiating cells dimethylamine and sarcosine are seen in both the control
vs. curcumin and control vs. dual treatment; glycine is significantly impacted in control vs
curcumin; lactate and β-alanine are significantly impacted in control vs. OPP; and glutamine is
significantly impacted in control vs. dual treatment.
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CHAPTER 4
Discussion
4.1 Discussion
People of all ages can suffer from depression; the overall quality of life is decreased
because the disorder can affect how individuals are able to function on a daily basis, it is also
affected by the high risk for relapse after treatment. The overall health burden is also present in
multiple facets of life, including individually, in the workplace, and within the family. From an
individual perspective, residual symptoms of depression may linger even after treatment has been
administered. Within the workplace, it has been reported that 27 days per year per depressed
employee are lost, due to either the calling in sick, or being at work but not functioning at an
efficient level. Depression can also alter family structures, causing instability, and possibly
completely disrupting the home life.(75) Overall, we did see the potential antidepressant activity
OPP may have within neuronal RN46A-B14 cells in the serotonin pathway; we also saw that there
are additional metabolic changes that have occurred, which need to be further elucidated.
Cell viability is an important aspect to consider when determining treatment doses. In
certain instances, such as with cancer cells, decreased cell viability is preferred; however, in
neuronal cells treatment should not be overly toxic. We found, through the MTS assay, what range
of treatment dosage would be appropriate to use for both curcumin and OPP. Interestingly,
treatment dosages of 1-5 µM curcumin enhanced the viability of the RN46A-B14 proliferating
cells, with respect to the control, although the mechanism is not fully understood. Concentrations
at 10, 15, and 20 µM reduced the viability of the cells by 60, 81, and 86% respectively, as compared
to the control. The half maximal inhibitory concentration (IC50), or the concentration at which
treatment inhibits cell proliferation by half, is between 7.5-10 µM, but closer to 10 µM. Having

44
viability less than the control is understandable, as an additional component is being added to the
media, which may affect the overall cell viability; however, for this experiment we wanted to
minimize the adverse effects while maximizing the beneficial properties. Because of this, we
determined that a working range up to 7.5 µM curcumin could be tolerated. For OPP, we observed
that every dose of OPP decreased the viability of cells in relation to the control. A 5% dose of OPP
resulted in a 52% decrease in cell viability, while 7.5% and 10% dosages resulted in 53 and 57%
reduction in cell viability, respectively. The IC50 for OPP is around 5%; because of this we
believed that doses up to 3.75% would be acceptable for this study.
It has been suggested that a decrease in Asmt activity, with a subsequent decrease in
synthesis of melatonin, accumulation of Aanat may occur, leading to increased synthesis of
serotonin.(76; 77; 78) In our case, we believe that the reduction of expression of Aanat along with no
changes seen upstream in Tph1 and Tph2 or downstream in Asmt, results in a similar
mechanism. (76) Based on this mechanism, in addition to our data, we proposed a model,
demonstrating what we believe is the mechanism of action for OPP based on what was observed.
We supplemented the media of the neuronal cells with OPP, which caused a decrease in the
expression of Aanat. Because of this, we postulate that the expression of serotonin will increase,
as there were no other upstream or downstream alterations observed. This causes a “pooling” of
serotonin, which may result in decreasing the occurrence of depression. The mechanism is still not
fully understood, but may be an important novel treatment for those suffering from depression.
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Figure 4.1: Proposed model for the activity of OPP on serotonin pathway-related genes.
Tph1: tryptophan hydroxylase 1; Tph2: tryptophan hydroxylase 2; Ddc: dopa decarboxylase;
Aanat: aralkylamine N-acetyltransferase; Asmt: acetylserotonin O-methyltransferase.

The polyphenolic nature of both curcumin and OPP led us to believe that both compounds
may similarly affect the mechanism of depression. From a metabolomic standpoint, we did not see
any impact in the tryptophan pathway – the concentrations of tryptophan, serotonin, Nacetylserotonin and melatonin were too low to be calculated. Also, serotonin is typically excreted,
so may be present in the exometabolome/growth media. We have collected this, but further
analysis needs to be conducted. We observed that curcumin did not have any effect on the
regulation of serotonin metabolism in the differentiating cells. This could be because the scope of
our experiment was too focused, and we did not examine the pathway(s) that curcumin impacts.
The metabolomics data firstly showed that the metabolic profiles between proliferating and
differentiating cells differ; this is consistent to what we thought would be seen, as even though the
cells have the same origin, they express different morphologies. To better understand how the
treatments affected each subset of cells, PLS-DA was done, in which each treatment condition was
assigned a class. Both the proliferating cells and differentiating cells showed a similar pattern with
respect to the effect of treatment – the control and curcumin-treated cells displayed more similar
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metabolic profiles, while cells treated with OPP and dual treatment of OPP and curcumin exhibited
similar profiles. We further examined the effect of treatment, by comparing each treatment
condition of both subsets of cells to the control; this data showed that every treatment does have
some alterations in the metabolic profile, with respect to the control. However, based on the R 2
and Q2 values, where R2 is indicative of how well the data fits the model and Q 2 estimates the
predictive ability of the model, the models treated with OPP or dual-treatment of curcumin and
OPP exhibited better fitting of data as well as predictive abilities. We observed, based on class
segregation through OPLS-DA, that every treatment – curcumin, OPP, and dual treatment of
curcumin and OPP – exhibited different metabolic properties as compared to the control. Although
this is true, it is unlikely that curcumin had much of an impact on the metabolic profiles of the
proliferating or differentiating cells; the response seen in the dual treatment of OPP and curcumin
was mostly related to the effect of OPP. This is because the predictive nature of the models with
curcumin-treatment only was very poor, while the models involving OPP and dual treatment of
curcumin and OPP had increased predictive abilities.
Our main focus in this study was to examine the effects of treatment within the serotonin
pathway and determine if antidepressant properties may be present. From the metabolomic data,
we may be able to broaden the scope to focus on overall mood, anxiety, and other related disorders
such as schizophrenia or bipolar disorder. Sarcosine, which was responsible for alterations in all
metabolic pathways with treatment of curcumin (single and dual treatment) is of interest because
it is a competitive inhibitor of the type I glycine transporter, and is an N-methyl-D-aspartate
receptor (NMDAR) co-agonist, which is believed to enhance NMDAR function, which is believed
to be low among schizophrenics.(79) Sarcosine has been reported to have few or no side effects
with administration in humans of 2 grams/day for one week, exhibits antidepressant and

47
antipsychotic properties and may impact cognition in schizophrenia. (79; 80) Further studies may be
done to better examine the relationship between curcumin administration and changes in sarcosine
levels.
β-alanine may also be an important metabolite to target, as significant impacts of this
metabolite were only seen in the differentiating cells treated with OPP. Research has indicated that
a diet supplemented with β-alanine can result in anxiolytic effects, as well as cause alterations in
the concentration of 5-hydroxyindoleacetic acid – possibly related to anxiety, carnosine – acts as
an antioxidant and may have the ability to suppress ischemia in the brain, and BDNF, which is
believed to be related to both depression and anxiety.(81;

82)

Further, one study reported that

supplementation with β-alanine for 30 days reduced anxiety, and increased expression of BDNF
within the hippocampus of both younger and older rats. (83) This indicates that OPP may result in
similar findings, and needs to be further explored.
4.2 Conclusion/Future Direction
The utilization of cell culture allowed for there to be no issue with adherence to treatment
regimen, while also maintaining a controlled environment. Also, the biological replicates are more
likely to be almost identical to each other, as opposed to the heterogeneity that would be seen
within animals. While cell culture may allow for a certain mechanism to be elucidated, it does not
allow for a systemic understanding of changes that are occurring. This may cause changes that
were seen in vitro to not happen in vivo due to the presence of other signaling pathways and
intercellular connections or regulatory systems in place, to ensure that there is the maintenance of
homeostasis. Future in vivo studies need to be conducted in order to better understand how
supplementation with curcumin and/or OPP affects an organism, as a whole system.

48
For future analysis, studies can be done to examine the effect of curcumin, OPP, and dual
treatment of curcumin and OPP have on other pathways of interest, possibly illuminating other
therapeutic options for depression, as well as potentially discovering biomarkers for depression.
Analyzing the growth media that was collected can be done, to see if there are further metabolic
changes from cellular excretions that were not seen intracellularly. As we used total OPP for this
experiment, further studies could be done utilizing different fractions of OPP, which are made up
of different polyphenolic compounds. This may demonstrate that certain polyphenolic compounds
have a larger impact on overall metabolism, and result in a more potent nutraceutical. Treating the
cells with OPP and then inducing a stressor, or adding a stressor and then supplementation with
OPP can be done to examine whether the OPP is exhibiting preventative or is able to attenuate the
effects of stress, which can be present at an animal or human level with the presence of oxidative
stress or inherent day-to-day stressors. Also, this can show whether the antioxidative properties of
OPP, in addition to its other potential properties, are enhanced by the presence of oxidation within
the cells as compared to normal conditions. As the concentrations of metabolites within the
tryptophan pathway – including tryptophan, serotonin, and melatonin – were low, we could add
additionally tryptophan as a substrate to the growth media. We believe this will allow for more
tryptophan to be available for the synthesis (and subsequent excretion) of serotonin, allowing for
higher concentrations of these compounds to be present. Also, further investigation into the effect
OPP has on the expression of Aanat needs to be conducted, to determine whether this does increase
the synthesis of serotonin, and consequently can help to decrease the symptoms of depression,
perhaps by altering overall mood or emotions.
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Depression can be experienced by individuals of all ages, and can result in alterations of
mood, decreased ability to function, and fatigue. Current treatment involves pharmaceuticals,
which can result in adverse side effects, and there is a risk of relapse. Nutraceuticals are of interest
because they may be able to work as efficiently as current treatments, and will cause fewer adverse
effects. Curcumin and oil palm phenolics (OPP) are polyphenolic compounds that exhibit
beneficial properties, including anti-oxidant and anti-cancer, and may assist in the regulation of
diabetes. For this experiment, we utilized a neuronal rat cell line, RN46A-B14, which exhibits
proliferative and differentiating properties, to study the effect of supplementation of curcumin and
OPP on the regulation of the serotonin pathway as well as the metabolic profile, to discover
potential antidepressants. Real-time quantitative PCR was done to determine if curcumin and OPP
had any impact on the regulation of serotonin pathway-related genes. It was found that the
expression of Aanat in the differentiating cells was decreased. Western blot analysis was done to
examine the protein levels of tryptophan hydroxylase (TPH1 and TPH2), in which no significant
changes were seen within any treatment condition. 1H NMR analysis was also done, in which the
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metabolomics approach was used to determine if there were any changes in metabolic profiles of
treatment conditions; it was found that all treatment conditions did differ from the control, but the
OPP and dual treatment of curcumin and OPP exhibited the largest changes in metabolic profiles.
Overall, the study showed the potential serotonin enhancing ability of OPP within differentiating
cells.
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